The effect of desmopressin on reducing blood loss in children with congenital cyanotic heart disease undergoing cardiopulmonary bypass
Phase 1
Recruiting
- Conditions
- SurgeryPaediatricsAnaesthesia
- Registration Number
- PACTR202004798675261
- Lead Sponsor
- Mansoura university children hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
This study will be conducted on a total of 52 patients with CCHD undergoing CPB of either sex with their age ranging from 3 to 72 month.
Exclusion Criteria
Patients will be excluded from the current study in case of refusal of their guardians, redo cardiac surgery, pre existing coagulopathy, hepatic or renal dysfunction and history of allergy to desmopressin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does desmopressin utilize to reduce blood loss in congenital cyanotic heart disease patients undergoing cardiopulmonary bypass?
How does desmopressin compare to standard-of-care antifibrinolytic agents in reducing perioperative blood loss in pediatric cardiac surgery?
Are there specific biomarkers that can predict desmopressin response in children with congenital cyanotic heart disease during cardiopulmonary bypass?
What are the known adverse events associated with desmopressin use in pediatric patients undergoing cardiopulmonary bypass and how can they be managed?
What other vasoactive agents or combination therapies are being explored for blood loss reduction in congenital cyanotic heart disease surgeries?